Vaginal Candidiasis
12
3
3
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
8%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Postbiotic as Adjunct Treatment for Vaginal Candidiasis
Implementation of a Minor Ailment Service in Community Pharmacy Practice
Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis
Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
Women's Improvement of Sexual Health (WISH) Demonstration Project
Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis
Observational Program Neo-Penotran® Forte
Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis